Sort
30,917 grants matching “tumor microenvironment”
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance
$585,570Stephen H Safe · Texas A&M University · R01 · FY2023 · CA
Linking the microbiome and immune-checkpoint in melanoma by RNF5
$585,472Linda Mac Pherson Bradley · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2019 · CA
NSAIDs During Postpartum Involution for Breast Cancer Chemoprevention
$585,429Pepper J Schedin · Oregon Health & Science University · R01 · FY2015 · CA
In situ cancer cell specific biomineralization to overcome nanoparticle delivery barriers and sensitize pancreatic cancer to radiotherapy
$585,319Konstantin V Sokolov · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer
$585,317Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2025 · CA
Immune Responses in Otitis Prone Children
$585,306Michael E Pichichero · Rochester General Hospital (Ny) · R01 · FY2016 · DC
Project 2: Local immunotherapy corrects chemokine patterns in ovarian cancer
$585,174Robert Page Edwards · Roswell Park Cancer Institute Corp · P01 · FY2021 · CA
Tumor-Associated Macrophages in Vasogenic Cerebral Edema in Brain Tumors
$585,044Dolores Hambardzumyan · University Of Pennsylvania · R01 · FY2025 · NS
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
$585,015Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2022 · CA
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma
$584,972Evan Newell · Fred Hutchinson Cancer Center · R01 · FY2024 · CA
Molecular Analysis of Breast Cancer Metastasis to the Brain
$584,959Patricia Schriver Steeg · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors
$584,926Seth M Pollack · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA
Translation of a novel combination therapy approach for non-Hodgkin lymphoma
$584,891Shruthi Naik · Mayo Clinic Rochester · U01 · FY2022 · CA
The rodent eye as a non-invasive window for understanding cancer nanotherapeutics
$584,839Kit S Lam · University Of California At Davis · U01 · FY2015 · CA
Neutrophil derived proteinases abolish the IFNG signature in NSCLC
$584,823A. McGarry Houghton · Fred Hutchinson Cancer Center · R01 · FY2025 · CA
Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers
$584,773Evanthia Galanis · Mayo Clinic Rochester · R01 · FY2020 · CA
Towards True Precision Oncology: Validation of a Comprehensively Humanized, Autologous Mouse Model
$584,722Ryan C Fields · Washington University · R01 · FY2019 · CA
Decoding tumor metabolic and immunologic interactions driving racial disparity in African American patients with bladder cancer.
$584,631Nagireddy Putluri · Baylor College Of Medicine · R01 · FY2024 · CA
Clinical, molecular, and immune characterization of naturally occurring osteosarcoma in dogs
$584,628Robert B Rebhun · University Of California At Davis · U01 · FY2023 · CA
Subclonal determinants of radiation response in soft tissue sarcomas
$584,521Everett James Moding · Stanford University · R37 · FY2025 · CA
Development of high parameter spatial transcriptomics and proteomics for the study of tumor microenvironments
$584,510Kimberly R Jordan · University Of Colorado Denver · R50 · FY2025 · CA
Metformin for chemoprevention of lung cancer in obese subjects at high risk
$584,429Saikrishna Yendamuri · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
$584,415Isabelle Caroline Le Poole · Northwestern University At Chicago · R01 · FY2024 · HL
Applying pathomics to establish a biosignature for aggressive skin melanoma
$584,380Yvonne Margaret Saenger · Albert Einstein College Of Medicine · R01 · FY2024 · CA
Biological determinants of colorectal cancer outcomes in Latinos of diverseýancestral origins
$584,261Stephanie L. Schmit · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · CA